Episode 190 - July 24, 2026

What It Covers

Biotech Hangout Episode 190 covers the reopening IPO window via Scribe Therapeutics' early-stage $120M offering, reverse merger financing trends, Colossal Biosciences' $20-30B valuation round, the MX Biopharma CMO fraud scandal, DYNE Therapeutics' DMD BLA acceptance, and two upcoming FDA AdCom panels for Replimmune and Capricor.

Key Questions Answered

• •Early-Stage IPO Signal: When biotech markets peak, risk tolerance expands and earlier-stage companies access public markets — Scribe raised $120M with only an Australian TGA clearance in hand. Investors should treat preclinical or near-preclinical IPOs as a cycle indicator, not a green light; Sana Biotechnologies raised $600M at $4.5B pre-money in 2021 and has since collapsed in valuation.
• •Reverse Merger Evolution: Six biotech reverse mergers have now closed with $200M+ concurrent PIPE financings — up from three last year and one the year prior. This structure trades broad institutional exposure and sell-side research coverage for speed and lower fees. Investors entering these deals should expect a 6-12 month lag before the company builds a full public market following.
• •Narrative as Capital Strategy: Colossal Biosciences is pursuing a $20-30B private valuation by selling de-extinction as a story, not a proven revenue model. Biotech companies struggling to raise capital should study this: packaging science into a narrative that resonates beyond specialist investors demonstrably unlocks larger funding pools, regardless of clinical or commercial stage.
• •DMD Regulatory Benchmark: DYNE Therapeutics' BLA for z-rostodirsen received FDA acceptance with a late-January PDUFA date. The drug delivers materially higher dystrophin expression than Sarepta's exon-51 drug and shifts dosing from weekly to monthly. Given the low efficacy bar already set by approved PMO drugs, approval appears highly probable, making this a cleaner risk-reward setup than the investor debate suggests.
• •Science Communication Gap: Biotech TV's Boston summit embedded 20 science communicators — each with 400,000-500,000 social media followers — directly inside Moderna, Alnylam, and six other companies for lab tours and one-on-one scientist interviews. This model of connecting credentialed, high-reach communicators with corporate R&D teams offers a replicable template for countering misinformation at scale.